|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FANK1 |
Gene summary for FANK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FANK1 | Gene ID | 92565 |
| Gene name | fibronectin type III and ankyrin repeat domains 1 | |
| Gene Alias | HSD13 | |
| Cytomap | 10q26.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8TC84 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92565 | FANK1 | C21 | Human | Oral cavity | OSCC | 4.67e-03 | 1.85e-01 | 0.2678 |
| 92565 | FANK1 | C30 | Human | Oral cavity | OSCC | 6.66e-09 | 4.27e-01 | 0.3055 |
| 92565 | FANK1 | C08 | Human | Oral cavity | OSCC | 4.27e-09 | 1.69e-01 | 0.1919 |
| 92565 | FANK1 | LN38 | Human | Oral cavity | OSCC | 8.51e-03 | 5.99e-01 | 0.168 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00510907 | Oral cavity | OSCC | regulation of DNA-binding transcription factor activity | 221/7305 | 440/18723 | 9.06e-07 | 1.23e-05 | 221 |
| GO:00510917 | Oral cavity | OSCC | positive regulation of DNA-binding transcription factor activity | 134/7305 | 260/18723 | 2.52e-05 | 2.35e-04 | 134 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FANK1 | SNV | Missense_Mutation | novel | c.614C>T | p.Ala205Val | p.A205V | Q8TC84 | protein_coding | tolerated(0.34) | benign(0.239) | TCGA-KK-A8I7-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | leuprolide | SD |
| FANK1 | SNV | Missense_Mutation | novel | c.211G>C | p.Val71Leu | p.V71L | Q8TC84 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-KK-A8II-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | lupron | PD |
| FANK1 | SNV | Missense_Mutation | rs199770819 | c.236N>T | p.Thr79Met | p.T79M | Q8TC84 | protein_coding | deleterious(0) | benign(0.184) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |